Award & Investment Overview
Kāhu SiliconBio, a University of Edinburgh spinout, has secured £1.2 million from the German Federal Agency for Disruptive Innovation (SPRIN-D) to advance a next-generation hormone monitoring platform for women’s health.
Founded by Dr. James Flewellen and Professor Teuta Pilizota, the company is commercializing research from the University of Edinburgh’s Centre for Engineering Biology. The new funding will support development of the company’s next prototype as it adapts its continuous hormone sensing technology for women’s health applications.
The award builds on earlier commercialization support from the Industrial Biotechnology Innovation Centre (IBioIC) and complements previous funding from Scottish Enterprise, Innovate UK, Silicon Catalyst UK, and the Roslin Institute Campus Innovation Account.
Approach & Ecosystem Context
Kāhu SiliconBio demonstrates a strong university commercialization pathway built on sustained translational support from regional, national, and international innovation organizations.
The company’s technology originated within the University of Edinburgh’s Centre for Engineering Biology before progressing through multiple commercialization programs that reduced technical risk and positioned the company for continued product development. Support from IBioIC helped bridge early translational research, while subsequent funding from Scottish Enterprise, Innovate UK, and other innovation partners enabled continued prototype development.
From a Mind the GAP perspective, Kāhu SiliconBio illustrates how layered commercialization funding can help university spinouts mature complex healthcare technologies. Rather than relying on a single funding source, the company has advanced through successive proof-of-concept, translational, and innovation funding programs that collectively support progression toward commercial readiness.
The SPRIN-D award also highlights the increasing role of international innovation agencies in supporting university spinouts developing technologies with broad healthcare impact.
Innovation & Technology
Kāhu SiliconBio is developing a biological sensing platform capable of continuously monitoring hormone levels throughout the day.
Current hormone testing typically provides a single measurement at one point in time, offering limited insight into dynamic hormonal changes. Kāhu SiliconBio’s platform is designed to continuously track hormone fluctuations associated with sleep, nutrition, stress, and the menstrual cycle, providing significantly richer biological data.
The technology could improve understanding of hormone-related disorders while supporting more personalized diagnosis, disease monitoring, and treatment decisions for women’s health conditions.
Potential Market Uses and Applications
Kāhu SiliconBio
Potential Clinical Applications
- Women’s health diagnostics
- Hormone-related disease monitoring
- Endocrine disorder assessment
- Personalized hormone therapy
- Reproductive health monitoring
Potential Healthcare Applications
- Continuous hormone monitoring
- Precision medicine
- Clinical research
- Remote patient monitoring
- Digital biomarker development
Potential Commercial Applications
- Wearable biosensing platforms
- Continuous diagnostic technologies
- Life science research tools
- Women’s health technologies
Related Topics
University of Edinburgh, engineering biology, women’s health, biosensors, continuous monitoring, university spinouts, translational research, SPRIN-D, IBioIC, healthcare innovation
About innovosource
innovosource tracks GAP programs, including proof-of-concept programs, startup accelerators, translational research initiatives, university venture funds, and commercialization ecosystems that help move university innovations from research to market.
Our coverage is informed by the Mind the GAP Initiative and the GAP COA consortium activity, providing practical insights into the evolving commercialization landscape.
Learn more:
Source
LinkedIn Comment
Kāhu SiliconBio shows how sustained translational funding can move university research toward real-world healthcare impact. Layered support from commercialization programs has helped advance a promising biosensing platform with the potential to improve women’s health diagnostics and personalized care. Follow GAP Insights from innovosource for more university commercialization news.
